Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: A retrospective study

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Montemurro, Filippo ^a   Redana, Stefania ^a   Nolè, Franco ^b   Donadio, Michela ^c   Jacomuzzzi, Maria Elena ^d   Valabrega, Giorgio ^a   Viale, Giuseppe ^b   Sapino, Anna ^e   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Centro Oncologico Subalpino (COES)   (Italy)

^d MAURIZIANO HOSPITAL   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYTOSTATIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CENTRAL NERVOUS SYSTEM METASTASIS; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SOFT TISSUE METASTASIS; BIOSYNTHESIS; BREAST TUMOR; DISEASE COURSE; DRUG RESISTANCE; ENZYMOLOGY; GENE AMPLIFICATION; GENETICS; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SALVAGE THERAPY; VINBLASTINE;

EID: 49249094975     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-209     Document Type: Article

References (21)

1. Slamon DJ Clark GM Wong SG Levin WJ Ullrich A McGuire WL Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235:177-182 10.1126/science.3798106 3798106
2. Slamon DJ Leyland-Jones B Shak S Fuchs H Paton V Bajamonde A Fleming T Eiermann W Wolter J Pegram M Baselga J Norton L Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 2001, 344:783-792 10.1056/ NEJM200103153441101 11248153
3. Marty M Cognetti F Maraninchi D Snyder R Mauriac L Tubiana-Hulin M Chan S Grimes D Anton A Lluch A Kennedy J O'Byrne K Conte P Green M Ward C Mayne K Extra JM Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group J Clin Oncol 2005, 23:4265-4274 10.1200/JCO.2005.04.173 15911866
4. Pegram MD Konecny GE O'Callaghan C Beryt M Pietras R Slamon DJ Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 2004, 96:739-749 15150302
5. Montemurro F Valabrega G Aglietta M Trastuzumab-based combination therapy for breast cancer Expert Opin Pharmacother 2004, 5:81-96 10.1517/ 14656566.5.1.81 14680438
6. Fumoleau P Delgado FM Delozier T Monnier A Gil Delgado MA Kerbrat P Garcia-Giralt E Keiling R Namer M Closon MT. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy J Clin Oncol 1993, 11:1245-1252 8315421
7. Mano M Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy Cancer Treat Rev 2006, 32:106-118 10.1016/j.ctrv.2005.12.008 16473470
8. Depierre A Freyer G Jassem J Orfeuvre H Ramlau R Lemarie E Koralewski P Mauriac L Breton JL Delozier T Trillet-Lenoir V Oral vinorelbine: Feasibility and safety profile Ann Oncol 2001, 12:1677-1681 10.1023/ A:1013567022670 11843244
9. Burstein HJ Kuter I Campos SM Gelman RS Tribou L Parker LM Manola J Younger J Matulonis U Bunnell CA Partridge AH Richardson PG Clarke K Shulman LN Winer EP Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer J Clin Oncol 2001, 19:2722-2730 11352965
10. Chan A Martin M Untch M Gil MG Guillem-Porta V Wojtukiewicz M Kellokumpu-Lehtinen P Sommer HL Georgoulias V Battelli N Pawlicki M Aubert D Bourlard T Gasmi J Villanova G Petruzelka L Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial Br J Cancer 2006, 95:788-793 10.1038/sj.bjc.6603351 16969343
11. Chan A A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer Ann Oncol 2007, 18:1152-1158 10.1093/annonc/ mdl476 17264064
12. Catania C Medici M Magni E Munzone E Cardinale D Adamoli L Sanna G Minchella I Radice D Goldhirsch A Nole F Optimizing clinical care of patients with metastatic breast cancer: A new oral vinorelbine plus trastuzumab combination Ann Oncol 2007, 18:1969-1975 10.1093/annonc/ mdm372 17846020
13. Geyer CE Forster J Lindquist D Chan S Romieu CG Pienkowski T Jagiello-Gruszfeld A Crown J Chan A Kaufman B Skarlos D Campone M Davidson N Berger M Oliva C Rubin SD Stein S Cameron D Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 2006, 355:2733-2743 10.1056/NEJMoa064320 17192538
14. Montemurro F Valabrega G Aglietta M Lapatinib: A dual inhibitor of EGFR and HER2 tyrosine kinase activity Expert Opin Biol Ther 2007, 7:257-268 10.1517/14712598.7.2.257 17250463
15. Tripathy D Slamon DJ Cobleigh M Arnold A Saleh M Mortimer JE Murphy M Stewart SJ Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 2004, 22:1063-1070 10.1200/JCO.2004.06.557 15020607
16. Fountzilas G Razis E Tsavdaridis D Karina M Labropoulos S Christodoulou C Mavroudis D Gogas H Georgoulias V Skarlos D Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the hellenic cooperative oncology group Clin Breast Cancer 2003, 4:120-125 12864940
17. Gelmon KA Mackey J Verma S Gertler SZ Bangemann N Klimo P Schneeweiss A Bremer K Soulieres D Tonkin K Bell R Heinrich B Grenier D Dias R Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories Clin Breast Cancer 2004, 5:52-58 15140285
18. Montemurro F Donadio M Clavarezza M Redana S Jacomuzzi ME Valabrega G Danese S Vietti-Ramus G Durando A Venturini M Aglietta M Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy Oncologist 2006, 11:318-324 10.1634/ theoncologist.11-4-318 16614227
19. Miller AB Hoogstraten B Staquet M Winkler A Reporting results of cancer treatment Cancer 1981, 47:207-214 10.1002/ 1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 7459811
20. Montemurro F Aglietta M Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer? Nat Clin Pract Oncol 2007, 4:398-399 10.1038/ncponc0849 17549090
21. Von Minckwitz G Vogel P Schmidt M Eidtmann H Cufer T De Jongh F Maartense E Zielinski C Andersson M Stein R Nekljudova V Loibl S Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer - the TBP study (GBG 26/BIG 3-05) Breast Cancer Res Treat 2007, 106:S185-4056